Overview A Study in Participants With Acute Leukemia Status: Completed Trial end date: 2012-12-01 Target enrollment: Participant gender: Summary This study is a multicenter, non-randomized, open-label, Phase 2 study of intravenous LY2090314 in participants with acute leukemia. Phase: Phase 2 Details Lead Sponsor: Eli Lilly and Company